港股公告掘金 | 腾讯控股发布全年业绩，股东应占盈利2248.42亿元同比增加16% 末期股息每股5.3港元_老虎社区_美港股上老虎

港股公告掘金 | 腾讯控股发布全年业绩，股东应占盈利2248.42亿元同比增加16% 末期股息每股5.3港元

智通财经03-19

重大事项：圣贝拉集团(02508)与L Catterton达成战略合作共同打造跨领域的高端母婴与生活方式生态微创脑科学(02172)：APOLLO Dream®雷帕霉素靶向洗脱支架系统荣获FDA突破性医疗器械认定药捷安康-B(02617)：替恩戈替尼联合氟维司群用于经治失败的HR+/HER2-复发或转移性乳腺癌患者的II期临床完成首例患者给药开拓药业-B(09939)：KX-826酊1.0%治疗...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2620294150?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-19 09:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620294150","market":"us","top_or_hot":-1,"title":"港股公告掘金 | 腾讯控股发布全年业绩，股东应占盈利2248.42亿元 同比增加16% 末期股息每股5.3港元","media":"智通财经","content":"<div>\n<p>重大事项：圣贝拉集团(02508)与L Catterton达成战略合作 共同打造跨领域的高端母婴与生活方式生态微创脑科学(02172)：APOLLO Dream®雷帕霉素靶向洗脱支架系统荣获FDA突破性医疗器械认定药捷安康-B(02617)：替恩戈替尼联合氟维司群用于经治失败的HR+/HER2-复发或转移性乳腺癌患者的II期临床完成首例患者给药开拓药业-B(09939)：KX-826酊1.0%治疗...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1415726.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股公告掘金 | 腾讯控股发布全年业绩，股东应占盈利2248.42亿元 同比增加16% 末期股息每股5.3港元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股公告掘金 | 腾讯控股发布全年业绩，股东应占盈利2248.42亿元 同比增加16% 末期股息每股5.3港元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-19 09:10 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1415726.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>重大事项：圣贝拉集团(02508)与L Catterton达成战略合作 共同打造跨领域的高端母婴与生活方式生态微创脑科学(02172)：APOLLO Dream®雷帕霉素靶向洗脱支架系统荣获FDA突破性医疗器械认定药捷安康-B(02617)：替恩戈替尼联合氟维司群用于经治失败的HR+/HER2-复发或转移性乳腺癌患者的II期临床完成首例患者给药开拓药业-B(09939)：KX-826酊1.0%治疗...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1415726.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0577902454.USD","symbol_name":"FULLERTON LUX FUNDS - ASIA GROWTH & INCOME EQUITIE \"I\" (USD) ACC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1415726.html","article_id":"2620294150","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620294150","pubTimestamp":1773882658,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"重大事项：圣贝拉集团(02508)与L Catterton达成战略合作 共同打造跨领域的高端母婴与生活方式生态微创脑科学(02172)：APOLLO Dream雷帕霉素靶向洗脱支架系统荣获FDA突破性医疗器械认定药捷安康-B(02617)：替恩戈替尼联合氟维司群用于经治失败的HR+/HER2-复发或转移性乳腺癌患者的II期临床完成首例患者给药开拓药业-B(09939)：KX-826酊1.0%治疗中","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0577902454.USD":"FULLERTON LUX FUNDS - ASIA GROWTH & INCOME EQUITIE \"I\" (USD) ACC","LU1048588211.SGD":"Blackrock Asian Dragon A2 SGD-H","LU0048388663.USD":"SCHRODER ISF ASIAN OPPORTUNITIES \"A\" (USD) INC AV","LU1251922891.USD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (USD) ACC","LU0348723411.USD":"ALLIANZ GLOBAL HI-TECH GROWTH \"A\" (USD) INC","VXUS":"国际股票ETF-Vanguard","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","LU2498475776.HKD":"AMUNDI FUNDS REAL ASSETS TARGET INCOME \"A2\" (HKD) INC","LU0054237671.USD":"FIDELITY ASIAN SPECIAL SITUATIONS \"A\" INC","LU1366334578.USD":"ALLSPRING EMERGING MARKETS EQUITY INCOME \"A\" (USD) INC","LU1917777945.USD":"安联专题基金Cl AT Acc","LU0572944931.SGD":"Janus Henderson Horizon China Opportunities A2 SGD","LU0210533765.USD":"JPM GLOBAL GROWTH \"A\" (USD) ACC","LU1725190679.HKD":"SCHRODER ISF EMERGING MARKETS MULTI-ASSET \"A\" (HKD) INC MF","LU1226287529.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) ACC","LU0633140727.USD":"AB EMERGING MARKETS MULTI ASSET PORTFOLIO \"AD\" (USD) INC","HTCD.SI":"Tencent HK SDR 10to1","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","BK1531":"手游股","LU0348783233.USD":"安联东方收入型 CI A Dis美元","LU0791590937.USD":"ALLSPRING  EMERGING MARKTES EQUITY INCOME \"A\" (USD)","02617":"药捷安康-B","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","LU0918141705.HKD":"ALLIANZ TOTAL RETURN ASIAN EQUITY \"AM\" (HKD) INC","LU0648948544.HKD":"ALLIANZ ASIAN MULTI INCOME PLUS \"AM\" (HKD) INC","LU1568876335.HKD":"ALLIANZ CHINA MULTI INCOME PLUS \"AMG\" (HKD) INC","LU0611395673.USD":"NINETY ONE GSF EMERGING MARKETS EQUITY \"A\" (USD) ACC","IE00B031J352.USD":"FSSA GREATER CHINA GROWTH \"I\" (USD) INC","LU1316542783.SGD":"Janus Henderson Horizon Global Technology Leaders A2 SGD","02172":"微创脑科学","SG9999001689.USD":"施罗德亚洲成长股票","LU0572940350.SGD":"Janus Henderson Horizon Asian Dividend Income A3 SGD","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU1152091168.USD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" INC","LU2051468812.USD":"JPM EMERGING MARKETS ESG EQUITY \"A\" (USD) ACC","IE0008368411.USD":"FSSA ASIAN GROWTH \"I\" (USD) ACC","VIG":"股利增长指数ETF-Vanguard","LU0516422952.EUR":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (EUR) ACC","LU0048580855.USD":"富达大中华区A","LU1655091459.SGD":"JPM ASIA PACIFIC INCOME \"A\" (SGD) INC A","LU1196710864.SGD":"Schroder ISF Emerging Markets Multi-Asset A Dis SGD-H","LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD","HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","02508":"圣贝拉","LU0414403682.SGD":"Blackrock Asia Pacific Equity Income A5 SGD-H","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","LU1188198961.HKD":"SCHRODER ISF CHINA OPPORTUNITIES \"A\" (HKD) INC QV","00700":"腾讯控股","LU0328353924.USD":"UBS (LUX) EQUITY SICAV - GLOBAL EMERGING MARKETS OPPORTUNITY (USD) \"P\" (USD) ACC"},"translate_title":"Hong Kong Stock Announcement Nuggets | Tencent Holdings released its full-year results, and the profit attributable to shareholders was 224.842 billion yuan, an increase of 16% year-on-year. The final Dividend was HK$5.3 per share","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VXUS":1.5,"TCHmain":1.5,"02617":0.9,"VIG":1.5,"02172":0.9,"HTCD.SI":0.6,"02508":0.9,"00700":1.5},"content_text":"重大事项：圣贝拉集团(02508)与L Catterton达成战略合作 共同打造跨领域的高端母婴与生活方式生态微创脑科学(02172)：APOLLO Dream®雷帕霉素靶向洗脱支架系统荣获FDA突破性医疗器械认定药捷安康-B(02617)：替恩戈替尼联合氟维司群用于经治失败的HR+/HER2-复发或转移性乳腺癌患者的II期临床完成首例患者给药开拓药业-B(09939)：KX-826酊1.0%治疗中国成年男性雄激素脱发关键性临床试验III期阶段达到主要终点伊登软件(01147)附属与超聚变进行战略合作 推动算力与企业AI落地场景的结合五一视界(06651)：旗下两个平台SimOne及Dataverse已成功完成与NVIDIA Omniverse NuRec神经重建技术的深度整合和誉-B(02256)：FGFR2/3抑制剂ABSK061 获FDA授予孤儿药资格认定 用于治疗软骨发育不全经营业绩：华润电力(00836)发布年度业绩 股东应占利润145.19亿港元 同比增加0.9%中国铁塔(00788)发布年度业绩 股东应占利润116.3亿元 同比增长8.4%吉利汽车(00175)发布年度业绩 总收入同比上升25%达3452亿元 再度创下历史新高奇瑞汽车(09973)发布年度业绩 股东应占利润190.19亿元，同比增加34.6%腾讯控股(00700)发布全年业绩，股东应占盈利2248.42亿元 同比增加16% 末期股息每股5.3港元微博-SW(09898)发年度业绩 股东应占净利润为4.49亿美元 同比增长49.27%华住集团-S(01179)发布年度业绩 总收入253.07亿元 同比增加5.93%BOSS直聘-W(02076)2025年度净利润为26.905亿元，同比增加71.7%东曜药业-B(01875)发布年度业绩，收益7.48亿元 战略转型CDMO成果显著中海石油化学(03983)公布2025年业绩 拥有人应占溢利约9.74亿元 同比减少9.04%友邦保险(01299)发布年度业绩 新业务价值同比上升15%至55.16亿美元","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}